Atara Biotherapeutics Stock Falls After Surprise FDA Refusal to Approve Ebvallo

Atara Biotherapeutics Stock Falls After Surprise FDA Refusal to Approve Ebvallo

By Adriano Marchese Atara Biotherapeutics shares fell Monday after the company said the U.S. health regulator didn't approve its therapy, backtracking on its previous guidance. Shares fell...

Read Full Article →

📱 Tip: Tap the 🔗 Share icon in Safari and choose Add to Home Screen to install World Trade Factory.
INFINITY AI
Instagram Meta X LinkedIn Whatsapp